RESUMEN
One of the most common side effects of cancer treatment is cardiovascular disease, which substantially impacts long-term survivor's prognosis. Cardiotoxicity can be related with either a direct side effect of antitumor therapies or an accelerated development of cardiovascular diseases in the presence of preexisting risk factors. Even though it is widely recognized as an alarming clinical problem, scientific evidence is scarce in the management of these complications in cancer patients. Consequently, current recommendations are based on expert consensus. This Guideline represents SEOM's ongoing commitment to progressing and improving supportive care for cancer patients
No disponible
Asunto(s)
Humanos , Antineoplásicos/efectos adversos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/diagnóstico , Cardiotoxicidad/diagnóstico , Protocolos Antineoplásicos , Diagnóstico Precoz , Factores de Riesgo , Pruebas de Toxicidad/métodos , Pautas de la Práctica en MedicinaRESUMEN
Chemotherapy and radiotherapy often result in reduced fertility in cancer patients. With increasing survival rates, fertility is an important quality-of-life concern for many young cancer patients. Around 70-75% of young cancer survivors are interested in parenthood but the numbers of patients who access fertility preservation techniques prior to treatment are significantly lower. Moreover, despite existing guidelines, healthcare professionals do not address fertility preservation issues adequately. There is a critical need for improvements in clinical care to ensure patients are well informed about infertility risks and fertility preservation options and to support them in their reproductive decision-making prior to cancer treatment (AU)
No disponible
Asunto(s)
Humanos , Masculino , Femenino , Adolescente , Adulto Joven , Preservación de la Fertilidad/métodos , Preservación de la Fertilidad/normas , Neoplasias/complicaciones , Neoplasias/prevención & control , Factores de Riesgo , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/complicaciones , Salud Reproductiva/normas , Tratamientos Conservadores del Órgano/tendencias , Embarazo/fisiología , Preservación de Semen/tendenciasRESUMEN
We report a case of primary CNS lymphoma treated with high-dose methotrexate in the first line. After disease progression the patient received cranial radiotherapy with concomitant temozolomide, followed by rituximab plus temozolomide, with complete remission of the disease maintained for at least two years and without major toxicity (AU)
Asunto(s)
Humanos , Femenino , Persona de Mediana Edad , Anticuerpos Monoclonales/administración & dosificación , Antineoplásicos/administración & dosificación , Neoplasias del Sistema Nervioso Central/tratamiento farmacológico , Dacarbazina/análogos & derivados , Linfoma/tratamiento farmacológico , Anticuerpos Monoclonales de Origen Murino , Anticuerpos Monoclonales/uso terapéutico , Antineoplásicos/uso terapéutico , Cerebro/patología , Cerebro , Neoplasias del Sistema Nervioso Central/radioterapia , Dacarbazina/administración & dosificación , Dacarbazina/uso terapéutico , Irradiación Linfática/métodos , Imagen por Resonancia Magnética/métodosRESUMEN
We report the case of a 42 year-old woman with myasthenia gravis associated with a malignant thymoma. Despite surgery, chemotherapy and radiotherapy, the thymoma showed soft tissues, pleural and mediastinic progression. Unexpectedly, a complete remission of the thymoma was confirmed by FDG-PET after four cycles of immunoglobulins, administered as treatment for a myasthenic crisis. To our knowledge this is the first case report of complete remission of a malignant thymoma with immunoglobulin therapy (AU)